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Loc. S. Andrea delle Fratte, 06134 Perugia, ItalyThe last two decades have witnessed considerable interest
in the role of anti-hypertensive, anti-platelet and choles-
terol reducing agents in AAA patients being treated medi-
cally and in those undergoing surgery, but the quality of
evidence, overall, has been relatively weak. In 2004, an
elegant retrospective study by Kertai et al. suggested that
statins (when added to beta-blockers) could significantly
improve outcomes in AAA patients undergoing surgery.1
This was (potentially) a very important message and led
to many corroborative studies being undertaken, but even
today, there is no substantial evidence to support the
efficacy of beta-blockers and statins in non-cardiac
vascular patients.
Kertai et al. reviewed outcomes in 570 patients under-
going open AAA repair and concluded that the use of either
statins (OR 0.24; 95%CI 0.10e0.70), or beta-blocker (OR
0.24, 95%CI 0.11e0.54) or both was independently associ-
ated with significant reductions in the composite endpoint
of perioperative mortality and myocardial infarction (MI).1
Patients using a combination of statins and beta-blockers
appeared to be at lower risk for the composite endpoint
across multiple cardiac risk strata: patients with 3 or more
risk factors experienced significantly lower perioperative
events.
However, subsequent to this, Goodney et al. reported
outcomes from a larger study from the Vascular Study
Group of New England and failed to show any relevant
decrease in post-operative MI in 926 patients with AAA who
were treated with beta-blockers for at least one month
before repair, though there was some evidence of benefit in
higher-risk patients.2 Furthermore, the potential harms of
overusing drugs such as beta-blockers in patients withDOI of original article: 10.1016/j.ejvs.2004.07.008.
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recent POISE and other similar studies.3,4
The timing, dosage, and safety of drugs that currently
constitute optimal medical therapy for patients undergoing
AAA surgery have also been questioned. The American
College of Cardiology guidelines on perioperative cardio-
vascular risk management recommend continuing beta-
blockers only in patients who are already on them (Class
I, Level C) and to probably initiate beta-blocker therapy
(titrated to heart rate and blood pressure) only in those
patients with high cardiac risk (Class Ia, Level B).5,6 Of most
practical relevance, the guidelines do not recommend the
use of beta-blockers to reduce the risk of AAA expansion or
rupture (level of evidence: strong).6 Older studies had
suggested that beta-blocker therapy might reduce aneu-
rysm expansion, whereas subsequent randomized clinical
trials clearly showed these drugs to be ineffective.
The suggestions regarding a role for statins in preventing
AAA expansion/rupture are interesting. There have been
speculations that statins may modulate AAA growth,
leading to hopes that they might reduce AAA expansion.
Matrix metalloproteinase (MMP) expression (closely related
to aneurysm formation) was found to be decreased in
human AAA specimens of patients taking statins, while
other observational studies have found a decreased AAA
expansion rate with the use of statins.7 However, because
a clear relationship between total cholesterol levels and
AAA expansion rate has never been demonstrated, it seems
likely that benefit accorded by statins may be due to its
“pleiotropic” effect.7,8
Although these links are intriguing, as of today, there is
no conclusive proof that statins reduce aneurysm
growth.9e11 The evidence is mainly provided by small, non-
randomized, observational or animal-model studies. A
recent large meta-analysis of studies on statins and AAA by
Twine et al. indicated that claims that statins reduce AAA
expansion were based on low-quality evidence and was notd by Elsevier Ltd. All rights reserved.
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analysis of 11,933 individuals from 12 studies concluded
that there was a non-significant difference in AAA expan-
sion with statin therapy (difference 0.14 mm/year; 95%CI
0.33 to 0.05; p Z 0.16).10 Takagi et al. found only five
studies in their meta-analysis that focused on expansion
rates and statin therapy in AAA patients. All were obser-
vational and not randomized.11 Even though pooled data
showed a statistically lower expansion rate for statin
takers, heterogeneity among the studies was high and, of
more relevance, data also suggested that the inhibitory
potential result of statins on AAA enlargement was depen-
dent on AAA diameter, since the effect was evident only in
larger aneurysms (46 mm vs <40 mm).11 If this is true,
should we expect statins to have a role in the management
of AAA smaller than 45 mm?
At the same time, it is highly unlikely that anyone will be
able to undertake large-scale randomized trials. This is
because AAA and coronary disease patients share common
risk factors (smoking, hypertension) and many would
consider it unethical not to initiate statin therapy.
Regardless of the speculative role in modulating aneurysm
growth, the use of statins has consistently been shown to be
associated with improved early and long-term outcomes,
decreased AAA operative risks12 and, of most relevance,
reduced long-term mortality and cardiovascular mortality/
morbidity.7,12,13 These data are robust and are supported
by randomized trials.7,12,13
So, should we continue to administer statins and beta-
blocker to all patients with AAA? Beta-blockers should
probably be used in patients at the highest cardiac risk,while
in the lowest risk categories it is important to balance the
risks (e.g. hypotension, bradycardia, etc.) and benefits of
treatment. The use of statins should be more liberal. It is
unlikely that there will be large-scale randomized trials in
patients with small AAAs and it is probably correct to accept
AAA as being a “coronary heart disease equivalent” forwhich
aggressive secondary prevention guidelines apply to improve
perioperative and long-term morbidity and mortality.References
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